- authorisedTherapeutic use (Phase IV)
A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.
This study looks at how people with Parkinson's disease use a device called OraFID and a special app to take their Flexilev medicine. It aims to understand how well they use it and how they feel about it over 12 weeks.
Sweden - active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This study is looking into a new treatment called prasinezumab for people in the early stages of Parkinson's disease. Researchers want to see if it's safe and helps improve symptoms. Participants will either receive the new medicine or a dummy treatment, called a placebo.
United States · Austria · Canada - recruitingPHASE1
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
This study is testing a new drug for early Parkinson's disease called ALN-SNCA. Researchers want to see if it's safe, how the body handles it, and if it can lower a protein linked to Parkinson's. It's a first step to see if this treatment might help slow the disease.
Canada · Netherlands